Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …

This study investigates the intricate interplay between Metabolic-associated Fatty Liver
Disease (MAFLD) and COVID-19, exploring the impact of MAFLD on disease severity …

Background The presence of metabolic syndrome (MS) is associated with increased
disease severity in patients with coronavirus disease 2019 (COVID-19). Non-alcoholic fatty …

It is important to identify risk factors for poor outcomes of coronavirus disease 2019 (COVID-
19) patients. Currently, the correlation between non-alcoholic fatty liver disease (NAFLD) …

Background Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable
population that may be susceptible to more severe COVID-19. Moreover, not only the …

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty
liver disease (MAFLD) are on the rise like any other liver disease, and tend to affect 25% of …

Background People living with human immunodeficiency virus (PLWH) are at an increased
risk of nonalcoholic fatty liver disease (NAFLD) but how these patients react to COVID-19 …

Abstract The coronavirus disease 2019 (COVID-19) pandemic may present with a broad
range of clinical manifestations, from no or mild symptoms to severe disease. Patients with …

We read with great interest the article by Fan et al 1 published in Clinical Gastroenterology
and Hepatology on clinical features of COVID-19-related liver functional abnormality. This …

Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in
liver injury. However, few studies investigated liver injury in patients with COVID‐19 with …